Spurned By NICE On Avastin In Bowel Cancer, Roche Looks To U.K. Cancer Drugs Fund
This article was originally published in The Pink Sheet Daily
Executive Summary
NICE's definitive decision against Avastin in bowel cancer forces Roche to turn to Cancer Drugs Fund.
You may also be interested in...
NICE Rejects Avastin For Ovarian Cancer On Cost, Okays Lucentis
NICE has knocked back Avastin for ovarian cancer due to high cost, but Roche may have a plausible market strategy in place for the drug in the UK.
Avastin's Next Stop May Be Hearing As FDA Starts Withdrawal Process For Breast Cancer Claim
Agency officials stress that FDA is eager to work with Genentech on future studies to identify a subpopulation of responders.
Avastin's Stumble Again At NICE Underscores Importance Of Overall Survival Data
NICE rejection of Roche's Avastin comes a week ahead of target dates for U.S. and EU decisions on possibly withdrawing the indication, but still offers instructive lessons for working with technology assessment groups.